Premium
Regulation of ecto‐apyrase CD39 (ENTPD1) expression by phosphodiesterase III (PDE3)
Author(s) -
Baek Amy E.,
Kanthi Yogendra,
Sutton Nadia R.,
Liao Hui,
Pinsky David J.
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.13-234625
Subject(s) - phosphodiesterase 3 , milrinone , cilostazol , phosphodiesterase , apyrase , chemistry , rolipram , western blot , endocrinology , medicine , pharmacology , microbiology and biotechnology , biochemistry , biology , enzyme , heart failure , aspirin , gene
The ectoenzyme CD39 suppresses thrombosis and inflammation by suppressing ATP and ADP to AMP. However, mechanisms of CD39 transcriptional and post‐translational regulation are not well known. Here we show that CD39 levels are modulated by inhibition of phosphodiesterase 3 (PDE3). RAW macrophages and human umbilical vein endothelial cells (HUVECs) were treated with the PDE3 inhibitors cilostazol and milrinone, then analyzed using qRT‐PCR, immunoprecipitation/Western blot, immunofluorescent staining, radio‐thin‐layer chromatography, a malachite green assay, and ELISA. HUVECs expressed elevated CD39 protein (2‐fold [ P <0.05] for cilostazol and 2.5‐fold [ P <0.01] for milrinone), while macrophage CD39 mRNA and protein were both elevated after PDE3 inhibition. HUVEC ATPase activity increased by 25% with cilostazol and milrinone treatment ( P <0.05 and P <0.01, respectively), as did ADPase activity (47% and 61%, P <0.001). There was also a dose‐dependent elevation of soluble CD39 after treatment with 8‐Br‐cAMP, with maximal elevation of 60% more CD39 present compared to controls (1 mM, P <0.001). Protein harvested after 8‐Br‐cAMP treatment showed that ubiquitination of CD39 was decreased by 43% compared to controls. A DMSO or PBS vehicle control was included for each experiment based on solubility of cilostazol, milrinone, and 8‐Br‐cAMP. These results indicate that PDE3 inhibition regulates endothelial CD39 at a post‐translational level.—Baek, A. E., Kanthi, Y., Sutton, N. R., Liao, H., Pinsky, D. J. Regulation of ecto‐apyrase CD39 (ENTPD1) expression by phosphodiesterase III (PDE3). FASEB J . 27, 4419–4428 (2013). www.fasebj.org